Evidence map›Paper›PMID 22573317›Full record

ArticleThe Journal of biological chemistry2012

Biophysical and functional analyses suggest that adenovirus E4-ORF3 protein requires higher-order multimerization to function against promyelocytic leukemia protein nuclear bodies.

Vadim Patsalo, Mark A Yondola, Bowu Luan, Ilana Shoshani, Caroline Kisker, David F Green, Daniel P Raleigh, Patrick Hearing

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1γ sumoylation and poly-SUMO chain elongation.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vadim PatsaloDepartment of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York 11794, USA.
Mark A Yondola
Bowu Luan
Ilana Shoshani
Caroline Kisker
David F Green
Daniel P Raleigh
Patrick Hearing
Stony Brook University · USApplied Mathematics (United States) · US

Funding

Training Program in Pharmacological SciencesT32GM007518 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GARCIA-DIAZ, MIGUEL · 1985 to 2021
$5.4M
Regulation of Nuclear Signaling Pathways by the Adenovirus E4-ORF3 ProteinR01CA122677 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HEARING, PATRICK · 2007 to 2022
$5.2M
VIRAL ONCOLOGYT32CA009176 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HEARING, PATRICK · 1985 to 2012
$5.2M
Biophysical Studies of Amyloid Formation by Polypeptide HormonesR01GM078114 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI RALEIGH, DANIEL P · 2008 to 2024
$5.1M
Design of virucidal lectins targeting HIV.R01GM086199 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GREEN, DAVID F · 2009 to 2013
$1.4M
NCI NIH HHS CA009176NCI NIH HHS CA122677NCI NIH HHS R01 CA122677NCI NIH HHS T32 CA009176NIGMS NIH HHS GM007518NIGMS NIH HHS GM078114NIGMS NIH HHS GM086199NIGMS NIH HHS R01 GM078114NIGMS NIH HHS R01 GM086199NIGMS NIH HHS T32 GM007518
6 · The paper itself

Abstract

The early region 4 open reading frame 3 protein (E4-ORF3; UniProt ID P04489) is the most highly conserved of all adenovirus-encoded gene products at the amino acid level. A conserved attribute of the E4-ORF3 proteins of different human adenoviruses is the ability to disrupt PML nuclear bodies from their normally punctate appearance into heterogeneous filamentous structures. This E4-ORF3 activity correlates with the inhibition of PML-mediated antiviral activity. The mechanism of E4-ORF3-mediated reorganization of PML nuclear bodies is unknown. Biophysical analysis of the purified WT E4-ORF3 protein revealed an ordered secondary/tertiary structure and the ability to form heterogeneous higher-order multimers in solution. Importantly, a nonfunctional E4-ORF3 mutant protein, L103A, forms a stable dimer with WT secondary structure content. Because the L103A mutant is incapable of PML reorganization, this result suggests that higher-order multimerization of E4-ORF3 may be required for the activity of the protein. In support of this hypothesis, we demonstrate that the E4-ORF3 L103A mutant protein acts as a dominant-negative effector when coexpressed with the WT E4-ORF3 in mammalian cells. It prevents WT E4-ORF3-mediated PML track formation presumably by binding to the WT protein and inhibiting the formation of higher-order multimers. In vitro protein binding studies support this conclusion as demonstrated by copurification of coexpressed WT and L103A proteins in Escherichia coli and coimmunoprecipitation of WT·L103A E4-ORF3 complexes in mammalian cells. These results provide new insight into the properties of the Ad E4-ORF3 protein and suggest that higher-order protein multimerization is essential for E4-ORF3 activity.

Indexed as

AdenoviridaeAdenoviridae InfectionsAdenovirus E4 ProteinsBiophysicsCell NucleusDimerizationHeLa CellsHost-Parasite InteractionsHumansMultiprotein ComplexesMutagenesisNuclear ProteinsPromyelocytic Leukemia ProteinProtein Interaction Domains and MotifsRecombinant ProteinsTranscription FactorsAdenovirus E4 ProteinsMultiprotein ComplexesNuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinRecombinant ProteinsTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID22573317
PMCPMC3391147
OpenAlexW1987371953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.